Response to growth hormone therapy in experimental ischemic acute renal failure

Fernando C. Fervenza, Fay W. Hsu, Tanny Tsao, Michael M. Friedlaender, Ralph Rabkin

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

In acute renal failure (ARF), the gene and peptide expression of insulin-like growth factor-I (IGF-I) falls. Because IGF-I is regulated by growth hormone (GH) and because kidney GH receptor expression is also attenuated in ARF, the impaired IGF-I expression may partly reflect local GH resistance. Because IGF-I treatment accelerates recovery from ARF, we determined whether high-dose GH therapy could overcome this putative GH resistance, stimulate IGF-I production, and enhance recovery. Rats with ARF were given 2.5 mg GH or vehicle (V) over 2 days, beginning 24 hours before the onset of ARF. GH prevented weight loss but did not modify the course of ARF. Next we determined whether the failure of GH to modify kidney recovery could reflect a failure to stimulate renal IGF-I gene expression. Rats were treated with GH orV over an 18-hour period beginning 1 day after the induction of ARF. Hepatic IGF-I mRNA and serum IGF-I peptide levels rose significantly with GH treatment, but the low kidney IGF-I mRNA levels did not respond. We conclude that the failure of GH to enhance recovery from ARF is caused by impaired GH-stimulated renal IGF-I production, while the maintenance of body weight likely reflects the systemic effects of the increase in hepatic IGF-I production.

Original languageEnglish (US)
Pages (from-to)434-439
Number of pages6
JournalJournal of Laboratory and Clinical Medicine
Volume133
Issue number5
DOIs
StatePublished - Jan 1 1999

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Response to growth hormone therapy in experimental ischemic acute renal failure'. Together they form a unique fingerprint.

  • Cite this